Showing results (51-60 of 198) with videos related to

Sort By:
Pageof 20
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 29, 2011
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]Kouki Kuwabara, Kensuke Kumamoto, Keiichiro Ishibashi, et al.
Biotechnology Advances|June 3, 2008
Protein and lysate array technologies in cancer researchBrett Spurrier, Peter Honkanen, Antonia Holway, et al.
Molecular and Clinical Oncology|September 1, 2017
Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancerKensuke Kumamoto, Hideyuki Ishida, Koki Kuwabara, et al.
Annals of Nuclear Medicine|December 18, 2015
Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?Shirou Ishii, Daisuke Shimao, Takamitsu Hara, et al.
Molecular Cell|March 23, 2005
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expressionMinori Koshiji, Kenneth K-W To, Stefanie Hammer, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 13, 2011
[Pseudo-Meigs' syndrome caused by ovarium metastasis from colorectal cancer]Masatsugu Ishii, Keiichiro Ishibashi, Jun Sobajima, et al.
Oncology Letters|November 9, 2017
CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancerMotonobu Saito, Hirokazu Okayama, Katsuharu Saito, et al.
Oncology Letters|January 19, 2018
L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancerSuguru Hayase, Kensuke Kumamoto, Katsuharu Saito, et al.
Oncology Letters|October 19, 2013
Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patientsKensuke Kumamoto, Keiichiro Ishibashi, Norimichi Okada, et al.
Pageof 20